Literature DB >> 22

[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities].

M Ardenne, P G Reitnauer.   

Abstract

A report is given on the recent discovery of outstanding immunological properties in BA 1 [N-(2-cyanoethylene)-urea] having a (low) molecular mass M = 111.104. Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1.7 percent), results in a recovery rate of 40 percent without hyperglycemia and, in one test, of 80 percent with hyperglycemia. Under otherwise unchanged conditions the reference substance ifosfamide (IF) -- a further development of cyclophosphamide -- applied without hyperglycemia in its most efficient dosage of 47 percent LD50 (150 mg kg) brought about a recovery rate of 25 percent at a lethality of 18 percent. (Contrary to BA 1, 250-min hyperglycemia caused no further improvement of the recovery rate.) However this comparison is characterized by the fact that both substances exhibit two quite different (complementary) mechanisms of action. Leucocyte counts made after application of the said cancerostatics and dosages have shown a pronounced stimulation with BA 1 and with ifosfamide, the known suppression in the post-therapeutic interval usually found with standard cancerostatics. In combination with the cited plaque test for BA 1, blood pictures then allow conclusions on the immunity status. Since IF can be taken as one of the most efficient cancerostatics--there is no other chemotherapeutic known up to now that has a more significant effect on the DS carcinosarcoma in rats -- these findings are of special importance. Finally, the total amount of leucocytes and lymphocytes as well as their time behaviour was determined from the blood picture of tumour-free rats after i.v. application of BA 1. The thus obtained numerical values clearly show that further research work on the prophylactic use of this substance seems to be necessary and very promising.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 22

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  12 in total

1.  Inequalities in outcomes of acute kidney injury in England.

Authors:  K A Abraham; E B Thompson; K Bodger; M Pearson
Journal:  QJM       Date:  2012-03-08

2.  Acute kidney injury associates with increased long-term mortality.

Authors:  Jean-Philippe Lafrance; Donald R Miller
Journal:  J Am Soc Nephrol       Date:  2009-12-17       Impact factor: 10.121

3.  Estimating baseline kidney function in hospitalized patients with impaired kidney function.

Authors:  Edward D Siew; T Alp Ikizler; Michael E Matheny; Yaping Shi; Jonathan S Schildcrout; Ioana Danciu; Jamie P Dwyer; Manakan Srichai; Adriana M Hung; James P Smith; Josh F Peterson
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-15       Impact factor: 8.237

4.  Defining acute kidney injury in database studies: the effects of varying the baseline kidney function assessment period and considering CKD status.

Authors:  Jean-Philippe Lafrance; Donald R Miller
Journal:  Am J Kidney Dis       Date:  2010-07-29       Impact factor: 8.860

5.  Use of electronic results reporting to diagnose and monitor AKI in hospitalized patients.

Authors:  Nicholas M Selby; Lisa Crowley; Richard J Fluck; Christopher W McIntyre; John Monaghan; Nigel Lawson; Nitin V Kolhe
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 8.237

6.  Early nephrologist involvement in hospital-acquired acute kidney injury: a pilot study.

Authors:  Geetha Balasubramanian; Ziyad Al-Aly; Abdul Moiz; Michael Rauchman; Zhiwei Zhang; Rajalakshmi Gopalakrishnan; Sumitra Balasubramanian; Tarek M El-Achkar
Journal:  Am J Kidney Dis       Date:  2010-12-31       Impact factor: 8.860

7.  The initial development and assessment of an automatic alert warning of acute kidney injury.

Authors:  Mark Thomas; Alice Sitch; George Dowswell
Journal:  Nephrol Dial Transplant       Date:  2010-12-08       Impact factor: 5.992

8.  An assessment of the RIFLE criteria for acute renal failure in hospitalized patients.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Donna Goldsmith; Samantha Bates; Claudio Ronco
Journal:  Crit Care Med       Date:  2006-07       Impact factor: 7.598

9.  Acute kidney injury in a Chinese hospitalized population.

Authors:  Yi Fang; Xiaoqiang Ding; Yihong Zhong; Jianzhou Zou; Jie Teng; Ying Tang; Jing Lin; Pan Lin
Journal:  Blood Purif       Date:  2010-08-14       Impact factor: 2.614

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  4 in total

1.  On the optimization of local hyperthermy in tumors based on a new radiofrequency procedure. Local hyperthermy of large body areas using the CMT selectotherm method.

Authors:  M von Ardenne; G Böhme; E Kell
Journal:  J Cancer Res Clin Oncol       Date:  1979-06-08       Impact factor: 4.553

2.  Human Pentraxins Bind to Misfolded Proteins and Inhibit Production of Type I Interferon Induced by Nucleic Acid-Containing Amyloid.

Authors:  Stephanie M Dorta-Estremera; Wei Cao
Journal:  J Clin Cell Immunol       Date:  2015-06-23

3.  DGCR8/miR-106 Axis Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinomas by Downregulating RUNX3.

Authors:  Chunlin Zhang; Hangqi Chen; Zeyi Deng; Dan Long; Li Xu; Zhaohui Liu
Journal:  Front Med (Lausanne)       Date:  2020-12-15

Review 4.  Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review.

Authors:  Olivier Bonnot; Hans Hermann Klünemann; Frederic Sedel; Sylvie Tordjman; David Cohen; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2014-04-28       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.